• Twitter
  • Linkedin
  • EN EN EN en
  • FR FR FR fr
Qynapse
  • HOME
  • CLIENTS
    • Pharmas
    • Healthcare providers
  • SOLUTIONS
    • QyScore®
    • QyPredict®
  • ABOUT
    • Team
    • Partners
  • CAREERS
  • CONTACT
  • NEWS
  • FR
  • Search
  • Menu

Support for advanced diagnosis, drug efficacy and safety monitoring for central nervous system diseases

– Automated quantification of a broad portfolio of
clinically-relevant imaging markers

– Easy comparison with normative dataset of healthy subjects
– Intuitive user interface for in-depth analysis
– Automated reporting with clear-cut results

CE-marked and FDA-cleared

INTEGRATED WITH LEADING MRI SCANNERS AND RIS/PACS SYSTEMS

Support for advanced diagnosis, drug efficacy and safety monitoring for central nervous system diseases

– Automated quantification of a broad portfolio of
clinically-relevant imaging markers

– Easy comparison with normative dataset of healthy subjects
– Intuitive user interface for in-depth analysis
– Automated reporting with clear-cut results

CE-marked and FDA-cleared

INTEGRATED WITH LEADING MRI SCANNERS AND RIS/PACS SYSTEMS

BENEFITS

CLINICAL

Improves diagnosis, monitoring and likelihood of observing longitudinal changes by eliminating inter-/intra-rater variability.

↓ 89%*

of inter-rater variability on average for white matter lesions

COST & TIME

Reduction of time and cost of image analysis.


↓ 80%**

of time and cost compared to manual segmentation performed by experts



* Qynapse study – comparison between automated quantification of white matter lesions and expert manual segmentation
– using published data (Commowick, O., Istace, A., Kain, M. et al. Sci Rep 8, 13650. 2018)

** Based on Qynapse estimation


IMAGING MARKERS

Grey and white matter

3DT1

Amygdala and hippocampus

3DT1

Local volumes

3DT1

Basal ganglia and thalamus

3DT1

Cerebellum

3DT1

Brain stem

3DT1

Spinal cord

3DT1

WMH*

T2-FLAIR

WMH* follow-up

T2-FLAIR

Diffusion MRI

BOLD and ASL

fMRI

FDG, Amyloid and Tau

PET

Grey and white matter

3DT1

Amygdala and hippocampus

3DT1

Local volumes

3DT1

Basal ganglia and thalamus

3DT1

Cerebellum

3DT1

Brain stem

3DT1

Spinal cord

3DT1

WMH*

T2-FLAIR

WMH* follow-up

T2-FLAIR

Diffusion MRI

BOLD and ASL

fMRI

FDG, Amyloid and Tau

PET

*WMH = White matter hyperintensities

Markers differ according to the regulatory approved version (FDA or CE) but all markers can be supplied for research or clinical trial purposes.

Request a demo
Request a demo

 

 

Qynapse is a medical technology company that unlocks the potential of quantitative imaging and AI to optimize diagnosis, prognosis and longitudinal monitoring of patients with neurological diseases.

Follow Us on TwitterFollow Us on LinkedIn

PARTNERS

twitter

  • Qynapse is pleased to sponsor #ACTRIMSForum 2021 – established to advance the research and clinical care of multipl… https://t.co/KJPuq7p83I14 hours ago
  • As a founding member of the Decentralized Trials & Research Alliance @DTRAorg, we look forward to the collaboration… https://t.co/MkPrmyZmiu30 days ago
  • Qynapse wishes you a Happy New Year 2021! We look forward to continue with exciting collaborations this year – to d… https://t.co/fMjDxQFUq851 days ago
  • By advancing #decentralizedtrials we can make clinical trials more patient-focused, diverse and efficient, and leve… https://t.co/z8ck93CH7Y56 days ago

CONTACT

Qynapse (Paris)
130, rue de Lourmel
75015 Paris – France

Qynapse (Boston)
50 Milk St, 16th Floor
Boston, MA, 02119 – USA

contact[@]qynapse.com

© 2019 QYNAPSE ALL RIGHTS RESERVED - Privacy policy
Scroll to top

This website uses cookies. By continuing to browse our website, you are agreeing to our use of cookies.
For more information, see our privacy policy

OKPrivacy policy